Critical Care Research and Practice / 2010 / Article / Tab 1

Case Report

Safety and Efficacy of Erythropoietin in Traumatic Brain Injury Patients: A Pilot Randomized Trial

Table 1

Characteristics of patients receiving erythropoietin or placebo.

Characteristic (SD)EPOPlacebo -value
( = 11)( = 5)

Age35 (19)40 (26)NS
Male73%60%NS
Admit GCS4.7 (3.3)8.8 (5.3).04
Admit SBP130 (33)115 (26)NS
Admit HR91 (18)78 (18)NS
ICU GCS11 (3.6)9.8 (4.9)NS
Sedation on arrival73%40%NS
ISS27 (8.4)21.6 (8.4)NS
Head AIS4 (0.6)3.8 (0.4)NS
Midline shift (mm)2.0 (3.4)0 (0)
EAH grade6.0 (8.1)0.3 (0.6)
SDH grade4.2 (7.3)0 (0)
EDH grade1.8 (5.3)0.3 (0.6)NS
ICH grade11.5 (12.7)5.6 (9.0)NS
SAH grade3.2 (1.0)3 (1.4)NS

GCS: Glascow Coma Score, SBP: Systolic Blood Pressure, HR: Heart Rate, ICU GCS: first recorded GCS in the ICU, ISS: Injury Severity Score, AIS: Abbreviated Injury Severity Score, EAH: Extra-axial Hemorrhage, SDH: Subdural Hemorrhage, EDH: Epidural Hemorrhage, ICH: Intracranial Hemorrhage, SAH: Subarachnoid Hemorrhage.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.